Photo from wikipedia
In June 2015, the Thai Rheumatism Association (TRA) approved an update of its recommendation for the use of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic (tsDMARD) in the treatment… Click to show full abstract
In June 2015, the Thai Rheumatism Association (TRA) approved an update of its recommendation for the use of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic (tsDMARD) in the treatment of rheumatoid arthritis (RA) to cover those currently available in Thailand (etanercept, infliximab, golimumab, rituximab, tocilizumab, abatacept and tofacitinib).
Keywords:
use biologic;
rheumatism association;
thai rheumatism;
modifying anti;
anti rheumatic;
disease modifying
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!